Program
Rifaximin
Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.
Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.
Drug pageRifaximin: every studyAll 150 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companiesits history only | 161 open or running | phase 4since Apr 16, 2013 | Dec 22, 2005 | Apr 20, 2027phase 4 · NCT07285785 |
| Alfasigma | 40 open or running | phase 2since Feb 19, 2015 | Feb 19, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jul 9, 2015 | Jul 9, 2015 | none ahead |
Also a collaborator on its studies: bioRASI, Cromsource and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alfasigma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2015First study: phase 2 study in Vaginosis, BacterialFirst studyNCT02376972 · 392 enrolled · United States
- May 15, 2018Phase 2 study in Crohn DiseaseNCT03537157 · 43 enrolled · Italy
- Mar 5, 2019Phase 2 study in RosaceaNCT03864978 · 236 enrolled · Italy
- Oct 25, 2021Phase 2 study in RosaceaNCT05150587 · 216 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 4 Alfasigma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05150587Rosacea · United States | 2 | Completed | Oct 20, 2022 | 216 |
| NCT03864978Rosacea · Italy | 2 | UNKNOWN | Apr 2020 | 236 |
| NCT03537157Crohn Disease · Italy | 2 | Terminated | Jul 15, 2020 | 43 |
| NCT02376972Vaginosis, Bacterial · United States | 2 | Terminated | Feb 2016 | 392 |
How it is read
Names in the registry
- “Rifaximin”, 12 entries
- “Rifaximin 200 mg Tablet”, 1 entry
- “Low Dose Rifaximin ER”, 1 entry
- “High Dose Rifaximin ER”, 1 entry
- “Rifaximin delayed release tablets”, 1 entry
Conditions, from the studies’ own filings
- Diarrhea, 7 studies
- Hepatic Encephalopathy, 4 studies
- Rosacea, 2 studies
- Anemia, Sickle Cell, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.